Roche's Valcyte approved for paediatric patients in the US
This article was originally published in Scrip
Executive Summary
The US FDA has granted Roche's Valcyte (valganciclovir HCl) supplemental approval for the treatment of cytomegalovirus (CMV) disease in paediatric patients who have received heart or kidney transplants.